Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 16/20 | 0.62 |
| ▸ | HRH1 | P35367 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418355 | 0.81 | SSTR5 (0.59) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL2419790 | 0.79 | SSTR5 (0.61) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL2420636 | 0.78 | SSTR5 (0.55) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL3569693 | 0.76 | SSTR5 (1.00) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL2417488 | 0.76 | SSTR5 (0.60) | SSTR5HRH1HTR2BSSTR1 | |
| SCHEMBL6667100 | 0.76 | HTT (0.64) | KMT2A | |
| SCHEMBL2418311 | 0.75 | SSTR5 (0.57) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1872924 | 0.75 | SSTR5 (0.60) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL3974409 | 0.75 | GAA (0.53) | GAAKMT2A | |
| SCHEMBL3577450 | 0.74 | SSTR5 (0.76) | SSTR5HRH1KCNH2HTR2BSSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | claimed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | claimed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | claimed |
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | disclosed |
| US-7754744-B2 | Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885HRH1 156/4885GAA 1390/4885 |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885HRH1 156/4885GAA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.